ALLR - Allarity rallies on conclusion of mid-stage trial for its ovarian cancer treatment after showing clinical benefit
2024-05-02 09:01:39 ET
More on Allarity Therapeutics
- Allarity Therapeutics receives Nasdaq-approved extension to regain compliance
- Seeking Alpha’s Quant Rating on Allarity Therapeutics
- Historical earnings data for Allarity Therapeutics
- Financial information for Allarity Therapeutics